Welcome to Idorsia

Idorsia announces
financial results for
the first half of 2019

We've made
outstanding
progress
in 2018 -
interested to
learn more?

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

26 Jul 2019	Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
23 Jul 2019	Idorsia announces financial results for the first half of 2019
13 Jun 2019	Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio

Event	When
Nine-months 2019 Financial Results reporting*	October 22, 2019
Full-Year 2019 Financial Results reporting*	February 6, 2020
First Quarter 2020 Financial Results reporting*	April 23, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:30:51 CET

24.42 CHF

+0.20 (+0.83 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland